目的：研究头孢唑肟(Cef)在未透析肾衰病人的药物动力学,为临床合理用药提供依据.方法:HPLC法测定血浆和尿中Cef的浓度,结果:单剂量iv Cef 16.7 mg kg~(-1),病人血药浓度变化呈二室开放模型,主要药物动力学参数:V_d 0.55±0.17 L kg~(-1);AUC 879±461mg L~(-1)h;Cl 27+11 mL kg~(-1)h~(-1).T)((1/2)β)为15土4h.结论:肾衰患者T_((1/2)β)约是正常志愿者的11倍,感染时用药方案需调整,或延长用药间隔,或减少用药剂量. Objective: To study the pharmacokinetics of ceftizoxime (Cef) in non-dialysis patients with renal failure and provide a basis for rational clinical use.Methods: The concentration of Cef in plasma and urine was determined by HPLC method.Results: Single Cef 16,7 mg kg ~ (-1). The change of plasma concentration showed a two-compartment open model. The main pharmacokinetic parameters were as follows: V_d 0.55 ± 0.17 L kg -1; AUC 879 ± 461 mg L -1 h; Cl 27 + 11 mL (-1) h ~ (-1) .T) ((1/2) β) was 15 ± 4 h.Conclusion: T _ ((1/2) β) in patients with renal failure is about 11 Times, infection medication programs need to be adjusted, or to extend the interval of medication, or reduce the dosage.